Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar- Manual for Tracking down One of a kind Store Inns
- Medicine doesn’t just have ‘conscientious objectors’ − there are ‘conscientious providers,’ too
- Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
- The Force of Care: Living with Goal
- The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
- Consumers advised to dispose of 19 cooking pans due to lead leaching risk, FDA reports
